Bristol-Myers Squibb is an API and finished-dose manufacturer based in United Arab Emirates. It appears in 5,468 regulatory filings across 49 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, DIGEMAPS (DO) and EMA. Its GMP standing is certified by MHRA (UK), EMA and UZPHARM (UZ), among 11 authorities. Its most recent recorded inspection, by US FDA, closed on 18 July 2025 as VAI. Customs aggregates show $9K of exports covering 962 molecules to 5 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Manati, United Arab Emirates | Not on file |
| Manati, United Arab Emirates | Not on file |
| Utrecht, United Arab Emirates | Not on file |
| Boudry, United Arab Emirates | Not on file |
| Quebec, United Arab Emirates | Not on file |
| QQuebec, United Arab Emirates | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Saxagliptin | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| Health Canada | 1,908 | None |
| DIGEMAPS (DO) | 458 | None |
| EMA | 339 | 10 |
| US FDA | 305 | 4 |
| INHRR (VE) | 270 | None |
| AIFA (IT) | 204 | None |
| MHRA (UK) | None | 14 |
| UZPHARM (UZ) | None | 5 |
| MFDS (Korea) | None | 4 |
| HSA (SG) | None | 3 |
| NAFDAC (NG) | None | 3 |
| ANVISA (Brazil) | None | 2 |
| COFEPRIS (MX) | None | 2 |
| EAEU_EEC | None | 1 |
| EDA (EG) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | $48.2B | $9K | 5 |
| 2024 | $48.3B | $7K | 6 |
| 2023 | $45.0B | $794 | 4 |
| 2022 | Not reported | $2K | 2 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Bristol-Myers Squibb comes back tiered against every other supplier able to file there.
Start for free